This week, we will discuss whether the time has come to add mineralocorticoid antagonism to the RAS armamentarium. Can we surmount the hyperkalemia which is the commonest problem with these drugs? Let’s find out with FIDELIO.
Background
This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.
Background
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
Background
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
